Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
This page provides a historical news archive for Verve Therapeutics, Inc. (former Nasdaq: VERV), a clinical-stage company that has focused on developing genetic medicines for cardiovascular disease. News coverage about Verve highlights its work on in vivo base editing and single-course gene editing medicines intended to permanently turn off genes in the liver that drive atherosclerotic cardiovascular disease and high-risk lipid disorders.
Articles in this feed describe Verve’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – which target PCSK9, ANGPTL3, and LPA, respectively. News items detail clinical trial progress for VERVE-102 in the Heart-2 Phase 1b study in adults with heterozygous familial hypercholesterolemia and premature coronary artery disease, including reported dose-dependent reductions in LDL-C and PCSK9 protein levels and safety observations from early cohorts. Other updates cover the Pulse-1 Phase 1b trial of VERVE-201 in refractory hypercholesterolemia and homozygous familial hypercholesterolemia, as well as preclinical and collaboration milestones for VERVE-301 aimed at lowering lipoprotein(a).
In addition to clinical and regulatory updates, the news stream includes announcements about U.S. FDA Fast Track designation for VERVE-102, investigational new drug clearance, equity inducement grants, investor conference participation, and quarterly pipeline summaries. A significant portion of the coverage also relates to Eli Lilly and Company’s agreement to acquire Verve, the tender offer for Verve’s common stock, and the completion of the merger that resulted in Verve becoming an indirect wholly-owned subsidiary of Eli Lilly.
Because Verve’s common stock has been delisted from Nasdaq and the company has suspended its SEC reporting obligations, this page functions as a historical record of VERV-related news, useful for investors and researchers analyzing the development of single-course gene editing approaches in cardiovascular disease and the corporate events leading to Verve’s acquisition.
Verve Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for VERVE-102, a novel gene editing medicine targeting cardiovascular disease. The treatment is designed as a single-course therapy to inactivate the PCSK9 gene in the liver, aiming to permanently lower blood LDL cholesterol levels.
The ongoing Heart-2 Phase 1b clinical trial has shown promising interim results across three dose cohorts (0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg), with no treatment-related serious adverse events reported as of January 10, 2025. The company plans to announce initial safety and efficacy data in Q2 2025, with final dose escalation data expected in H2 2025.
The treatment targets patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). Verve will begin activating U.S. trial sites and plans to deliver an opt-in data package to Eli Lilly while initiating Phase 2 clinical trials in the second half of 2025.
Verve Therapeutics, a clinical-stage cardiovascular genetic medicine company, has granted equity awards to four new employees on February 28, 2025. The compensation package includes:
- 14,300 stock options with an exercise price of $6.33 per share (matching closing price)
- 20,100 restricted stock units (RSUs)
The stock options have a 10-year term with a 4-year vesting schedule: 25% vests after one year, with remaining shares vesting monthly over three years. RSUs will vest equally over three years starting April 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics reported key pipeline progress and financial results for Q4 and full year 2024. The company expects initial data from the Heart-2 Phase 1b trial of VERVE-102 (PCSK9 targeting) in Q2 2025, with final dose escalation data in H2 2025. VERVE-102 has shown positive safety profile with no serious adverse events.
The company maintains a strong financial position with $524.3 million in cash and equivalents, providing runway into mid-2027. Q4 2024 saw collaboration revenue of $13.1 million and a net loss of $50.0 million ($0.58 per share). For full year 2024, collaboration revenue was $32.3 million with a net loss of $198.7 million ($2.35 per share).
Key developments include ongoing enrollment in Pulse-1 Phase 1b trial of VERVE-201 targeting ANGPTL3, and the nomination of VERVE-301 targeting LPA gene. The company expects an opt-in decision from Eli Lilly in H2 2025.
Verve Therapeutics, a clinical-stage cardiovascular genetic medicine company, has granted equity awards to eight new employees on January 31, 2025. The compensation package includes:
- Stock options for 34,320 shares at $7.61 per share (closing price on grant date)
- 48,540 restricted stock units (RSUs)
The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. The RSUs will vest equally over three years, starting April 1, 2025. Both are subject to continued employment. These grants were made under the company's 2024 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics, a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's co-founder and CEO, Sekar Kathiresan, M.D., will engage in a fireside chat on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
The event will be accessible via a live webcast through the investor section of Verve's website at www.vervetx.com. For those unable to attend live, the presentation will remain archived on the website for 90 days following the event.
Verve Therapeutics, focused on genetic medicines for cardiovascular disease, announced significant updates and anticipated milestones for 2025.
Pipeline Progress: Initial data from the Heart-2 Phase 1b trial for VERVE-102 targeting PCSK9 is expected in Q2 2025. Dosing has progressed to the 0.6 mg/kg cohort. VERVE-301, targeting the LPA gene, has been nominated as a development candidate, with associated milestone payments from Eli Lilly.
Financial Outlook: The company is well-capitalized with a cash runway extending into mid-2027.
Collaborations: Eli Lilly holds an opt-in right for the PCSK9 program and will fund Phase 1 of the LPA program, with Verve eligible for up to $465 million in milestones and royalties.
Upcoming Events: Verve will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
Verve Therapeutics (VERV), a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Sekar Kathiresan, the company's co-founder and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT in San Francisco.
The presentation will be accessible through a live webcast on the investor section of Verve's website at www.vervetx.com. Interested parties can access the archived version of the webcast for 30 days following the presentation.
Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced new equity awards granted on December 31, 2024. The company issued 5,330 restricted stock units (RSUs) to one new employee under its 2024 Inducement Stock Incentive Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment. The RSUs will vest equally over four years, with annual installments beginning January 1, 2025, contingent on the employee's continued service with the company.
Verve Therapeutics, a clinical-stage biotechnology company focused on genetic medicines for cardiovascular disease, has granted 5,330 restricted stock units (RSUs) to a new employee under its 2024 Inducement Stock Incentive Plan. The grant, made on November 29, 2024, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over four years starting January 1, 2025, contingent on continued employment.
Verve Therapeutics reported progress in its clinical trials and Q3 2024 financial results. Seven participants were dosed in the Heart-2 Phase 1b trial of VERVE-102, with initial data expected in H1 2025. The first participant was dosed in the Pulse-1 Phase 1b trial of VERVE-201. The company reported $539.9M in cash and equivalents, with runway through 2026. Q3 financial results showed collaboration revenue of $6.9M, R&D expenses of $49.9M, and a net loss of $50.1M ($0.59 per share). VERVE-102 has been well-tolerated with no serious adverse events observed.